Myriad Genetics kept by Merrill at neutral

Myriad Genetics Inc. was reiterated by Merrill Lynch analyst David Munno at a neutral rating following news that the FDA did not suggest any modification of its phase III trial protocol amendment of Flurizan for Alzheimer's, that a majority of the sites approved the revised protocol and that enrollment is proceeding. Myriad Genetics shares Tuesday climbed $0.25, or 1.43%, to close at $17.77 on volume of 237,072 shares versus the three-month running average of 400,945 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.